Shattuck Labs Inc (STTK)
Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for inflammatory and immune-mediated diseases. Its lead program, SL-325, is a monoclonal antibody that blocks death receptor 3 and is being evaluated in a Phase I clinical trial for tumor necrosis factor-like ligand 1A-related treatment. The company is also advancing SL-425, a longer-acting version of SL-325, which is in IND-enabling chronic toxicology studies. In addition, Shattuck Labs is developing preclinical DR3-based bispecific antibodies for inflammatory bowel disease and other immune-mediated conditions, along with a TRIM7 program centered on oncology. Incorporated in 2016, the company is headquartered in Austin, Texas, and its common stock trades on the NASDAQ under the symbol STTK.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-STTK
|
$4.50
|
-37.2% Downside
|
Overvalued
|
$15
|
109.5% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-11.1x
|
5.8x
|
551.3x
|
523 M
|
463.8 M
|
0.5%
|
63.3%
|
43.2
|
—
|
82.9%
|
